Free Trial

Prenetics Global (NASDAQ:PRE) Raised to Hold at Wall Street Zen

Prenetics Global logo with Medical background

Wall Street Zen upgraded shares of Prenetics Global (NASDAQ:PRE - Free Report) to a hold rating in a report released on Saturday morning.

Prenetics Global Trading Up 1.2%

PRE traded up $0.10 during trading hours on Friday, hitting $8.11. The company's stock had a trading volume of 40,102 shares, compared to its average volume of 22,613. The company has a 50-day simple moving average of $7.71 and a 200 day simple moving average of $5.89. The firm has a market capitalization of $98.94 million, a PE ratio of -2.03 and a beta of 0.15. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $11.99.

Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings results on Thursday, June 12th. The company reported ($0.80) EPS for the quarter. Prenetics Global had a negative net margin of 115.91% and a negative return on equity of 28.07%. The business had revenue of $17.31 million for the quarter. Research analysts expect that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global at the end of the most recent reporting period. Institutional investors and hedge funds own 25.01% of the company's stock.

Prenetics Global Company Profile

(Get Free Report)

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.

Read More

Should You Invest $1,000 in Prenetics Global Right Now?

Before you consider Prenetics Global, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.

While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines